Bristol-Myers Squibb and Gilead Sciences received approval from the FDA for Atripla for the treatment of HIV-1 infection in adults. Atripla is the first-ever once-daily single tablet regimen (STR) for HIV intended as a stand-alone therapy or in combination with other antiretrovirals. The product combines Sustiva, manufactured by BMS, and Truvada, manufactured by Gilead Sciences. In December 2004 the two companies established a joint venture to develop and commercialize the STR. Truvada is a...